- Home
- JWEL vs QNRX Comparison
JWEL vs QNRX Comparison
Compare JWEL & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JWEL
- QNRX
- Stock Information
- Founded
- JWEL 2012
- QNRX 2018
- Country
- JWEL China
- QNRX United States
- Employees
- JWEL N/A
- QNRX N/A
- Industry
- JWEL Other Consumer Services
- QNRX Medical/Dental Instruments
- Sector
- JWEL Consumer Discretionary
- QNRX Health Care
- Exchange
- JWEL Nasdaq
- QNRX Nasdaq
- Market Cap
- JWEL 3.8M
- QNRX 3.3M
- IPO Year
- JWEL 2021
- QNRX N/A
- Fundamental
- Price
- JWEL $1.98
- QNRX $8.74
- Analyst Decision
- JWEL
- QNRX
- Analyst Count
- JWEL 0
- QNRX 0
- Target Price
- JWEL N/A
- QNRX N/A
- AVG Volume (30 Days)
- JWEL 8.2K
- QNRX 527.1K
- Earning Date
- JWEL 06-10-2025
- QNRX 05-13-2025
- Dividend Yield
- JWEL N/A
- QNRX N/A
- EPS Growth
- JWEL N/A
- QNRX N/A
- EPS
- JWEL N/A
- QNRX N/A
- Revenue
- JWEL $132,981,531.00
- QNRX N/A
- Revenue This Year
- JWEL N/A
- QNRX N/A
- Revenue Next Year
- JWEL N/A
- QNRX N/A
- P/E Ratio
- JWEL N/A
- QNRX N/A
- Revenue Growth
- JWEL N/A
- QNRX N/A
- 52 Week Low
- JWEL $1.06
- QNRX $5.01
- 52 Week High
- JWEL $3.71
- QNRX $54.95
- Technical
- Relative Strength Index (RSI)
- JWEL 47.86
- QNRX 58.38
- Support Level
- JWEL $1.90
- QNRX $8.44
- Resistance Level
- JWEL $2.18
- QNRX $9.90
- Average True Range (ATR)
- JWEL 0.13
- QNRX 0.89
- MACD
- JWEL -0.02
- QNRX 0.16
- Stochastic Oscillator
- JWEL 24.34
- QNRX 69.23
About JWEL Jowell Global Ltd.
Jowell Global Ltd is a cosmetics, health and nutritional supplements, and household products e-commerce platform. It operates under Online Direct Sales, Authorized Retail Store Distribution, Third-party Merchants, and Live streaming marketing sales channels. The company's major merchandise categories are Cosmetic products, Health and nutritional supplements, and Household Products.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.